D-Aspartic Acid

We are D-Aspartic Acid CAS:1783-96-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


D-Aspartic Acid
CAS RN: 1783-96-6
 

Solubility in 3M-HCl	Colorless & clear (c=5)
Specific rotation [α]D20	-24.7°～-25.8°(c= 8, 6M-HCl)
Loss on drying	Not more than 0.3%
Residue on ignition (as sulfate)	Not more than 0.1%
Chloride (Cl)	Not more than 0.03%
Sulfate (SO4)	Not more than 0.03%
Heavy metals (as Pb)	Not more than 10ppm
Iron (Fe)	Not more than 10ppm
Ammonium (NH4)	Not more than 0.02%
Arsenic (As2O3)	Not more than 1ppm
Other amino acids	Not detected by T.L.C.(The spotted amount, 20μg)
Assay	98.5%～101.0%
L-Isomer	Not more than 0.5%

 




Related News: “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.2-(TRIFLUOROMETHOXY)BENZOYL CHLORIDE CAS:162046-61-9 Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical.(S)-1-Boc-3-hydroxypiperidine CAS:143900-44-1 The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it. 3-fluoropiridina CAS:372-47-4 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).